About Afraxis
Afraxis was a Healthcare company based in San Diego (United States) founded in 2007. It provides comprehensive CNS pharmaceutical screening technologies for pre-clinical evaluations. It operates on a B2B model. Afraxis has raised $2 million across 3 funding rounds. Its Indian entity Ironsource India Private Limited reported revenue of ₹21.75 Cr. The company is recorded as dissolved. Its focus areas include Pharmaceuticals, Drug Screening and CNS Technologies. Its competitors include Lucid Scientific, Kiyatec and CytoTronics; 3 of its 3 listed competitors have raised funding.
Company details
Afraxis, founded in 2007 in San Diego, United States, focuses on providing healthcare solutions, producing pharmaceutical products, drug screening, and cns technologies. Provides comprehensive CNS pharmaceutical screening technologies for pre-clinical evaluations. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters San Diego, United States
- SectorsHealthcare
- Website afraxis.com
- Legal Name Ironsource India Private Limited
- Date of Incorporation 26 Apr, 2016
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹21.75 Cr
FY 2025 · +206% YoY
- Indian entity net profit₹3.79 Cr
FY 2025 · 17% margin
- Indian entity EBITDA₹5.88 Cr
FY 2025 · 27% margin
- Total Equity Funding$2M (USD)
in 3 rounds
- Latest Funding Round$45K (USD), Seed
Apr 2012
Associated legal entities of Afraxis
Afraxis operates through Ironsource India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ironsource India Private Limited CIN U74300KA2016FTC092539 | Active | 26 Apr 2016 | Bangalore, Karnataka | ₹21.7 Cr | 21 | 4 | View details |
Funding Insights of Afraxis
Afraxis has successfully raised a total of $2M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $45 thousand completed in April 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2M
- Total Rounds 3
- Last Round Seed — $45,000
- First Round $750,001
(Jun 2009)
All 5 funding rounds of Afraxis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $204,508 | Grant | – | – | |
| Apr 2012 | $45,000 | Seed | – | – | – |
| Dec 2011 | $300,000 | Debt – Conventional | – | – | – |
| May 2010 | $1.2M | Seed | – | – | – |
| Jun 2009 | $750,001 | Seed | – | – | – |
Board of directors of Ironsource India Private Limited (Afraxis)
Ironsource India Private Limited is the primary company behind Afraxis. The board of Ironsource India Private Limited currently have 4 directors; the longest-serving is Nora Sen Go, appointed in 2024. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nora Sen Go DIN 10531941 | Director | 04 Mar 2024 | 2 yrs 8 mo | Ironsource India Private Limited |
| Bhagavant Bedi DIN 08005696 | Director | 21 Nov 2024 | 1 yr 11 mo | Ironsource India Private Limited |
| Jasmine De Layton DIN 10792925 | Director | 08 Jul 2025 | 1 yr 4 mo | Ironsource India Private Limited |
| Shridhar Subbaraman Iyer DIN 07151577 | Director | 30 Oct 2025 | 1 yr | Ironsource India Private Limited |
Financials of Afraxis
Figures of Ironsource India Private Limited, the primary company behind Afraxis, for FY 2025. Revenue was ₹21.75 Cr (+206% year on year). Net profit was ₹3.79 Cr (17% margin). EBITDA was ₹5.88 Cr (27% margin). Revenue has grown at a compounded annual rate of +87% over three years and +59% over five years.
- ₹21.75 CrRevenue · FY 2025 · +206% YoY
- ₹3.79 CrNet profit · 17% margin
- ₹5.88 CrEBITDA · 27% margin
- ₹1 LakhPaid-up capital
- 21Employees (provident fund records)
- +87%Revenue CAGR, 3 years
- +59%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Ironsource India Private Limited are on its company page.
Detailed financial statements for Afraxis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Afraxis
3 dated milestones of Afraxis across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Afraxis is founded.
- Funding First funding round of $750K.
- Funding Latest funding round, Seed, of $45K.
Competitors of Afraxis
Afraxis has 3 listed competitors in our database, 3 of them funded. They include Lucid Scientific, Kiyatec and CytoTronics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lucidsci.com | 2012 | Atlanta, United States | $12.73M | Real-time cell analyzers are developed for oxygen consumption monitoring. | ||
| kiyatec.com | 2005 | Pendleton, United States | $29.49M | Kiyatec is focused on revolutionizing cancer care through predictive platforms. | ||
| cytotronics.com | 2015 | Boston, United States | $22.75M | 22 | Cell-based assays for drug discovery are developed via CMOS platform. |
Detailed competitors of Afraxis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Afraxis (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Afraxis
Complete news archive for Afraxis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Afraxis
Afraxis was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Afraxis is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Afraxis is a funded company, having raised a total of $2M across 3 funding rounds to date. The company's 1st funding round was a Seed of $750K, raised on Jun 2009.
The primary company behind Afraxis, Ironsource India Private Limited, reported revenue of ₹21.75 Cr for FY 2025, up 206% year on year.
Afraxis, founded in 2007 in San Diego, United States, focuses on providing healthcare solutions, producing pharmaceutical products, drug screening, and cns technologies. Provides comprehensive CNS pharmaceutical screening technologies for pre-clinical evaluations. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Afraxis's top competitors include CytoTronics, Kiyatec and Lucid Scientific.
Afraxis operates through Ironsource India Private Limited.
The legal entities of Afraxis currently have 4 directors, including Nora Sen Go, Bhagavant Bedi, Shridhar Subbaraman Iyer and others.